<p>The World Health Organization, which is currently reviewing Bharat Biotech's application for an Emergency Use Listing (EUL) of its Covid-19 vaccine Covaxin, has said it is assessing the data of the jab.</p>.<p>In an update on its website, the WHO, which began rolling data on July 6, said the date for a decision on the jab is yet "to be confirmed".</p>.<p>Rolling data allows the WHO to start its review right away, as information continues to come in, to accelerate the overall review process.</p>.<p><strong>Read | <a href="https://www.deccanherald.com/international/covaxin-recipient-infected-with-covid-19-delta-variant-dies-pfizer-moderna-recipients-recover-study-1008144.html" target="_blank">Covaxin recipient infected with Delta variant dies</a></strong></p>.<p>Suchitra Ella, joint managing director of Bharat Biotech, had recently said the EUL process is a step closer to the final decision on Covaxin's 'global acceptance' as the rolling data was slated to begin in July.</p>.<p>She also said in a tweet that the company was working closely with the WHO for inclusion of Covaxin in its EUL and approval is not expected to be a long drawn process as cell line and majority of Bharat Biotech's facilities have already been audited and approved by the global health watchdog for BBIL's other vaccines in the past.</p>.<p><strong>Read | <a href="https://www.deccanherald.com/business/bharat-biotechs-partner-ocugen-seeks-approval-for-covaxin-in-canada-1009240.html" target="_blank">Bharat Biotech partner seeks Covaxin approval in Canada</a></strong></p>.<p>The city-based vaccine maker recently said it concluded the final analysis of Covaxin efficacy from Phase 3 trials. The jab demonstrated 77.8 per cent effectiveness against symptomatic Covid-19 and 65.2 per cent protection against the B.1.617.2 Delta variant, it said.</p>
<p>The World Health Organization, which is currently reviewing Bharat Biotech's application for an Emergency Use Listing (EUL) of its Covid-19 vaccine Covaxin, has said it is assessing the data of the jab.</p>.<p>In an update on its website, the WHO, which began rolling data on July 6, said the date for a decision on the jab is yet "to be confirmed".</p>.<p>Rolling data allows the WHO to start its review right away, as information continues to come in, to accelerate the overall review process.</p>.<p><strong>Read | <a href="https://www.deccanherald.com/international/covaxin-recipient-infected-with-covid-19-delta-variant-dies-pfizer-moderna-recipients-recover-study-1008144.html" target="_blank">Covaxin recipient infected with Delta variant dies</a></strong></p>.<p>Suchitra Ella, joint managing director of Bharat Biotech, had recently said the EUL process is a step closer to the final decision on Covaxin's 'global acceptance' as the rolling data was slated to begin in July.</p>.<p>She also said in a tweet that the company was working closely with the WHO for inclusion of Covaxin in its EUL and approval is not expected to be a long drawn process as cell line and majority of Bharat Biotech's facilities have already been audited and approved by the global health watchdog for BBIL's other vaccines in the past.</p>.<p><strong>Read | <a href="https://www.deccanherald.com/business/bharat-biotechs-partner-ocugen-seeks-approval-for-covaxin-in-canada-1009240.html" target="_blank">Bharat Biotech partner seeks Covaxin approval in Canada</a></strong></p>.<p>The city-based vaccine maker recently said it concluded the final analysis of Covaxin efficacy from Phase 3 trials. The jab demonstrated 77.8 per cent effectiveness against symptomatic Covid-19 and 65.2 per cent protection against the B.1.617.2 Delta variant, it said.</p>